Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Madrigal Pharmaceuticals, Inc.

NASDAQ: MDGL · Life Sciences · 4 alerts · CIK 1157601

Share price
$423.96Close, Nov 16
Market cap
$9.85B
Shares outstanding
23.23MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Madrigal Pharmaceuticals, Inc. filings on SEC EDGAR ↗

5:31 PM ET Form 4
Insider Buying

Madrigal Pharmaceuticals Director Baker Bros. Advisors LP Buys $35M of Stock

Baker Bros. Advisors LP, Director, bought 91,806 shares of Madrigal Pharmaceuticals, Inc. at $366.99 to $396.61 a share (average $381.49) in 5 transactions, worth $35M in total between Nov 4, 2026 and Nov 6, 2026. Shares held after the trade: 2,040,682 (+0.1%).

Value
$35M
Shares
91,806
Average price
$381.49
Role
Director
Holding change
+0.1%
Trade date
Nov 4, 2026 to Nov 6, 2026
4:36 PM ET Form 4
Insider Selling

Madrigal Pharmaceuticals General Counsel Shannon T. Kelley Sells $431K of Stock

Shannon T. Kelley, General Counsel, sold 1,077 shares of Madrigal Pharmaceuticals, Inc. at $400.00 a share, worth $431K in total on Nov 6, 2026. Shares held after the trade: 10,397 (-9.4%).

Value
$431K
Shares
1,077
Price
$400.00
Role
General Counsel
Holding change
-9.4%
Trade date
Nov 6, 2026
9:11 AM ET 10-Q
Financial Results

Madrigal Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $55.4M

Madrigal Pharmaceuticals reported a significant increase in net product revenue to $431.3 million for the third quarter of 2026, resulting in a quarterly net income of $55.4 million compared to a net loss in the prior year. For the nine months ended September 30, 2026, the company maintained a net loss of $96.9 million as it continues to scale commercial operations for Rezdiffra.

Key figure
Net income $55.4M
8:10 AM ET 8-K
Financial Results

Madrigal Pharmaceuticals Financial Results

Madrigal Pharmaceuticals reported third-quarter 2026 financial results, highlighted by Rezdiffra net sales of $431.3 million and the achievement of its first quarter of profitability. The company also announced that Rezdiffra reached blockbuster status with year-to-date net sales of $1.1 billion and plans to initiate a new Phase 3 outcomes trial, MAESTRO-CSPH, in the first half of 2027.

“Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market.”

Bill Sibold, Chief Executive Officer of Madrigal

“Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH.”

Bill Sibold, Chief Executive Officer of Madrigal

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.